Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037059 | 0.90 | KMT2A (0.57) | KMT2AMEN1HPGDALDH1A1PDK2 | |
| SCHEMBL1002785 | 0.85 | NAMPT (0.56) | KMT2AMEN1HPGDALDH1A1PDK2 | |
| SCHEMBL2228900 | 0.84 | HPGD (0.59) | KMT2AMEN1HPGDALDH1A1PDK2 | |
| SCHEMBL2205042 | 0.84 | L3MBTL1 (0.48) | KMT2AMEN1HPGDALDH1A1PDK2 | |
| SCHEMBL22502136 | 0.83 | L3MBTL1 (0.50) | KMT2AMEN1HPGDALDH1A1PDK2 | |
| SCHEMBL18767368 | 0.82 | KMT2A (0.49) | KMT2AMEN1PDK2L3MBTL1 | |
| SCHEMBL3469796 | 0.81 | TPMT (0.48) | HPGDALDH1A1PDK2L3MBTL1NAMPT | |
| SCHEMBL5044031 | 0.81 | HPGD (0.57) | HPGDALDH1A1GAATSHRPLA2G4B | |
| Isophthalic Acid SCHEMBL11324134 | 0.81 | KMT2A (0.58) | KMT2ASMN1; SMN2TSHRPLA2G4B | |
| SCHEMBL6013406 | 0.80 | HDAC6 (0.55) | KMT2AMEN1HPGDNAMPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981913-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981913-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981913-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-02 | — | — | US | disclosed |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-02 | — | — | US | disclosed |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-02 | — | — | US | disclosed |
| US-7745470-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745470-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745470-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20060229309-A1 | Novel isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-12 | — | — | US | disclosed |
| WO-2006099352-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099352-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BACE1, APP, BACE2 | KMT2A 4117/4885MEN1 3443/4885HPGD 1756/4885 |
| US-20060229309-A1 | Novel isophthalates as beta-secretase inhibitors | BACE1, APP, BACE2 | KMT2A 4117/4885MEN1 3443/4885HPGD 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.